Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1

Mia Yang Chen, Steven David Rhodes, D. Clapp

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Neurofibromatosis type 1 (NF1) affects 1 in 3,500 people and is one of the most common genetic disorders with a predisposition to malignancy. NF1 is caused by autosomal dominant mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a negative regulator of Ras-activity. Cutaneous and plexiform neurofibromas, the hallmark tumors of NF1, are heterogeneous neoplasms composed of tumorigenic Schwann cells and a complex microenvironment, including mast cells, fibroblasts, and blood vessels. Emerging evidence indicates a pivotal role for interactions between Schwann cells, surrounding stroma, and hematopoietic constituents of the tumor microenvironment in promoting neurofibroma genesis. In NF1 mouse models, tumorigenic Nf1 nullizygous Schwan cells secrete supraphysiologic levels of stem cell factor (SCF), co-opting Nf1 haploinsufficient mast cells to infiltrate the tumor microenvironment. In turn, activated Nf1+/- mast cells secrete multiple inflammatory effectors which potentiate fibroblast proliferation, collagen deposition and angiogenesis, thereby creating a viscous cycle perpetuating neurofibroma maintenance and expansion. Experimental evidence from NF1 murine models indicates that either genetic or pharmacologic inhibition of SCF/c-kit dependent mast cell recruitment/activation is sufficient to treat neurofibromas in the NF1 murine model. A recent phase 2 clinical trial using Gleevec, which targets multi-tyrosine kinases including c-kit, provided the first evidence of an effective therapy for the treatment of plexiform neurofibromas. This chapter will review current clinical and animal model data delineating the role of the tumor microenvironment in neurofibroma pathogenesis and therapy.

Original languageEnglish (US)
Title of host publicationNeurofibromatosis: Diagnosis, Management and Clinical Outcomes
PublisherFuture Medicine Ltd.
Pages65-78
Number of pages14
ISBN (Print)9781634632485, 9781634632294
StatePublished - Oct 1 2014

Fingerprint

Plexiform Neurofibroma
Neurofibromatosis 1
Tumor Microenvironment
Neurofibroma
Mast Cells
Stem Cell Factor
Schwann Cells
Therapeutics
Fibroblasts
Neurofibromin 1
Neoplasms
Inborn Genetic Diseases
Tumor Suppressor Genes
Protein-Tyrosine Kinases
Blood Vessels
Collagen
Animal Models
Maintenance
Clinical Trials
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chen, M. Y., Rhodes, S. D., & Clapp, D. (2014). Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1. In Neurofibromatosis: Diagnosis, Management and Clinical Outcomes (pp. 65-78). Future Medicine Ltd..

Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1. / Chen, Mia Yang; Rhodes, Steven David; Clapp, D.

Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd., 2014. p. 65-78.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chen, MY, Rhodes, SD & Clapp, D 2014, Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1. in Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd., pp. 65-78.
Chen MY, Rhodes SD, Clapp D. Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1. In Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd. 2014. p. 65-78
Chen, Mia Yang ; Rhodes, Steven David ; Clapp, D. / Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1. Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd., 2014. pp. 65-78
@inbook{a225388d6c2243d88911727df2fe827f,
title = "Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1",
abstract = "Neurofibromatosis type 1 (NF1) affects 1 in 3,500 people and is one of the most common genetic disorders with a predisposition to malignancy. NF1 is caused by autosomal dominant mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a negative regulator of Ras-activity. Cutaneous and plexiform neurofibromas, the hallmark tumors of NF1, are heterogeneous neoplasms composed of tumorigenic Schwann cells and a complex microenvironment, including mast cells, fibroblasts, and blood vessels. Emerging evidence indicates a pivotal role for interactions between Schwann cells, surrounding stroma, and hematopoietic constituents of the tumor microenvironment in promoting neurofibroma genesis. In NF1 mouse models, tumorigenic Nf1 nullizygous Schwan cells secrete supraphysiologic levels of stem cell factor (SCF), co-opting Nf1 haploinsufficient mast cells to infiltrate the tumor microenvironment. In turn, activated Nf1+/- mast cells secrete multiple inflammatory effectors which potentiate fibroblast proliferation, collagen deposition and angiogenesis, thereby creating a viscous cycle perpetuating neurofibroma maintenance and expansion. Experimental evidence from NF1 murine models indicates that either genetic or pharmacologic inhibition of SCF/c-kit dependent mast cell recruitment/activation is sufficient to treat neurofibromas in the NF1 murine model. A recent phase 2 clinical trial using Gleevec, which targets multi-tyrosine kinases including c-kit, provided the first evidence of an effective therapy for the treatment of plexiform neurofibromas. This chapter will review current clinical and animal model data delineating the role of the tumor microenvironment in neurofibroma pathogenesis and therapy.",
author = "Chen, {Mia Yang} and Rhodes, {Steven David} and D. Clapp",
year = "2014",
month = "10",
day = "1",
language = "English (US)",
isbn = "9781634632485",
pages = "65--78",
booktitle = "Neurofibromatosis: Diagnosis, Management and Clinical Outcomes",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Targeting the tumor microenvironment for the treatment of plexiform neurofibromas in patients with neurofibromatosis type 1

AU - Chen, Mia Yang

AU - Rhodes, Steven David

AU - Clapp, D.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Neurofibromatosis type 1 (NF1) affects 1 in 3,500 people and is one of the most common genetic disorders with a predisposition to malignancy. NF1 is caused by autosomal dominant mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a negative regulator of Ras-activity. Cutaneous and plexiform neurofibromas, the hallmark tumors of NF1, are heterogeneous neoplasms composed of tumorigenic Schwann cells and a complex microenvironment, including mast cells, fibroblasts, and blood vessels. Emerging evidence indicates a pivotal role for interactions between Schwann cells, surrounding stroma, and hematopoietic constituents of the tumor microenvironment in promoting neurofibroma genesis. In NF1 mouse models, tumorigenic Nf1 nullizygous Schwan cells secrete supraphysiologic levels of stem cell factor (SCF), co-opting Nf1 haploinsufficient mast cells to infiltrate the tumor microenvironment. In turn, activated Nf1+/- mast cells secrete multiple inflammatory effectors which potentiate fibroblast proliferation, collagen deposition and angiogenesis, thereby creating a viscous cycle perpetuating neurofibroma maintenance and expansion. Experimental evidence from NF1 murine models indicates that either genetic or pharmacologic inhibition of SCF/c-kit dependent mast cell recruitment/activation is sufficient to treat neurofibromas in the NF1 murine model. A recent phase 2 clinical trial using Gleevec, which targets multi-tyrosine kinases including c-kit, provided the first evidence of an effective therapy for the treatment of plexiform neurofibromas. This chapter will review current clinical and animal model data delineating the role of the tumor microenvironment in neurofibroma pathogenesis and therapy.

AB - Neurofibromatosis type 1 (NF1) affects 1 in 3,500 people and is one of the most common genetic disorders with a predisposition to malignancy. NF1 is caused by autosomal dominant mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a negative regulator of Ras-activity. Cutaneous and plexiform neurofibromas, the hallmark tumors of NF1, are heterogeneous neoplasms composed of tumorigenic Schwann cells and a complex microenvironment, including mast cells, fibroblasts, and blood vessels. Emerging evidence indicates a pivotal role for interactions between Schwann cells, surrounding stroma, and hematopoietic constituents of the tumor microenvironment in promoting neurofibroma genesis. In NF1 mouse models, tumorigenic Nf1 nullizygous Schwan cells secrete supraphysiologic levels of stem cell factor (SCF), co-opting Nf1 haploinsufficient mast cells to infiltrate the tumor microenvironment. In turn, activated Nf1+/- mast cells secrete multiple inflammatory effectors which potentiate fibroblast proliferation, collagen deposition and angiogenesis, thereby creating a viscous cycle perpetuating neurofibroma maintenance and expansion. Experimental evidence from NF1 murine models indicates that either genetic or pharmacologic inhibition of SCF/c-kit dependent mast cell recruitment/activation is sufficient to treat neurofibromas in the NF1 murine model. A recent phase 2 clinical trial using Gleevec, which targets multi-tyrosine kinases including c-kit, provided the first evidence of an effective therapy for the treatment of plexiform neurofibromas. This chapter will review current clinical and animal model data delineating the role of the tumor microenvironment in neurofibroma pathogenesis and therapy.

UR - http://www.scopus.com/inward/record.url?scp=84957940191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957940191&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84957940191

SN - 9781634632485

SN - 9781634632294

SP - 65

EP - 78

BT - Neurofibromatosis: Diagnosis, Management and Clinical Outcomes

PB - Future Medicine Ltd.

ER -